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Abstract 
Current available anti-inflammatory drugs, in particular monoclonal antibodies directed against the 
cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of inflammatory bowel 
diseases (IBD). Although many patients respond to ant-TNF therapy, a proportion of patients will not 
respond (primary non-response) or will lose response to the drug over time (secondary non-
response). This loss of response can be caused by patient, TNF-inhibitor, or disease-related factors 
influencing the pharmacokinetics and pharmacodynamics of the drug. Therefore, monitoring 
pharmacological parameters (i.e. therapeutic drug monitoring) may help guide therapeutic decisions. 
This review emphasizes interesting and important new findings, and provides an updated overview, 
on the subject of therapeutic drug monitoring. While exploring the hypothesis that “one size does 
not fit all”, we focused on the first prospective studies investigating the novel approach in IBD of 
‘target concentration adjusted dosing’ and personalized medicine.  
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Introduction 
Most of the established and evolving therapies used in the treatment of inflammatory bowel disease 
(IBD) are also used to treat other chronic inflammatory conditions such as rheumatoid and psoriatic 
arthritis and ankylosing spondylitis. These anti-inflammatory drugs specifically interact with 
downstream targets of a shared inflammatory cascade. The monoclonal antibodies infliximab, 
adalimumab and golimumab and the antibody fragment certolizumab pegol all target the abundantly 
expressed cytokine tumor necrosis factor α (TNF). These biologicals remain to date the most 
efficacious tools in the pharmaceutical armamentarium to induce and maintain remission in patients 
with Crohn’s disease (CD) and ulcerative colitis (UC) (1-5). Although a drug can be administered for 
different indications based on its mode of action, a dose and its subsequent efficacy are much more 
difficult to extrapolate especially in the setting of complex biological drugs. 
Not only the pharmacokinetics (PK, referred to as what the body does to the drug) but also 
pharmacodynamics (PD, referred to as what the drug does to the body) can greatly differ between 
patients suffering from the same chronic inflammatory disease. From the literature, it is known that 
10–30% of IBD patients do not respond to TNF inhibitors (primary non responders) (6, 7). Across 
different trials and clinical case-series the annual risk for loss of response to infliximab and 
adalimumab was calculated to be, respectively, 13 and 24% as judged by the need for dose 
intensification (8, 9). Despite empiric dose intensification, the median drop-out rate from infliximab 
treatment was calculated to be 7% per year (10). Different factors can influence the non-response 
rate in patients and it is important to keep in mind that, especially in the setting of biologicals, the 
response towards the drug can fluctuate. These factors can be related to the patient (e.g., albumin, 
body size, and gender), disease (e.g., type, location, and severity) and the drug itself (e.g., synergism 
with immunosuppressive drugs and immunogenicity) (11).  
Immunogenicity is an important downside of biologic drugs, where the body recognizes the drug as 
non-self and the immune system develops anti-drug antibodies (ADA). These ADA hamper the 
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activity of the drug by causing a faster clearance and by blocking the binding site of the drug to TNF, 
and can also lead to allergic reactions. 
The heterogeneity in PK is probably not unique to TNF inhibitors, but it might be an intrinsic property 
of monoclonal antibodies. Therapeutic drug monitoring (TDM) at regular intervals can shed light on 
what is going on with the drug in vivo. The preferred time point of sampling is at trough (i.e. lowest 
concentration of drug just before the next administration). Drug trough concentrations (TC) are a 
pharmacological representation of the absorption, distribution, metabolization and excretion phase 
of the drug since its last administration (12). It can be hypothesized that a TC needs to be sufficiently 
high for the drug to exert maximal efficacy. On the other hand, a TC above this threshold will not 
result in increased (clinical) efficacy. This concept is often referred to as the optimal therapeutic 
window concept (13). 
Previous pivotal retrospective studies reported correlations between drug TC and clinical outcomes 
such as response, remission, and mucosal healing, supporting the concept of TDM in IBD clinical 
practice (14-17). This review’s goal is to emphasize new and important findings and to give an 
updated overview on the subject. By doing so, we chose to focus on the first prospective studies 
investigating this novel approach of ‘target concentration adjusted dosing’ and personalized 
medicine. 
Therapeutic Window Concept 
Therapeutic drug monitoring is important for the safety of drugs that have a narrow therapeutic 
window. For those drugs (e.g., digoxin) it is important to monitor that drug concentrations do not 
exceed a certain toxic concentration. On the other hand low or undetectable drug concentrations 
result in low efficacy. 
Anti-TNF drug and ADA concentrations can be measured using different assays. Recent comparison 
studies have shown that there can be differences in specificity and sensitivity among those assays 
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(18, 19). When measuring drug concentrations, an accurate standard can be available in the drug 
itself provided by the pharmaceutical company. In the case of measuring ADA, such a standard is not 
yet available which makes it difficult to compare absolute values obtained with different 
immunogenicity assays. Within the last few years, new assays have been developed which are able to 
measure ADA concentrations even in the presence of the drug (20, 21). Although it is still a matter of 
debate what the clinical relevance is of measuring ADA if an excess of active drug is still available in 
the patient’s serum, it appears that ADA in the presence of detectable drug leads to increased 
clearance of the drug. 
In the case of TNF inhibitors, the upper limit of the therapeutic window should be a reflection of a 
drug’s maximal efficacy, rather than toxicity. There is a lack of data on what is the optimal upper limit 
for the anti-TNF therapeutic window. However, this limit could greatly influence the cost-
effectiveness of anti-TNF treatment because dose reduction in patients with too high trough 
concentrations would result in significant cost savings. In relation to low concentrations, recent 
retrospective studies have suggested an optimal lower limit for infliximab and adalimumab TC in IBD 
patients: 
Infliximab Therapeutic Cut-Off 
A recent post hoc analysis of the ACT 1 and 2 studies showed that the proportion of UC patients 
achieving clinical response, remission and mucosal healing at weeks 8, 30, and 54 increased with 
increasing quartiles of infliximab concentrations (22). It was confirmed that this concentration-effect 
relationship reached a plateau. Specifically, the proportion of patients achieving clinical response, 
remission and mucosal healing did not increase above a certain infliximab concentration (Fig. 1). In a 
cohort study including 134 UC patients treated with maintenance infliximab, a TC cut-off >2 µg/ml 
was found to be associated with a higher rate of clinical steroid free remission (69 vs. 16%) for a 
median follow-up of 19.9 months (23). A meta-analysis of 2,021 serum samples from 532 CD patients 
included in 4 prospective randomized controlled trials or cohort studies evaluated the correlation 
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between infliximab concentration, ATI, and C-reactive protein (CRP) (24). Receiver operator curve 
analysis showed that an infliximab concentration >3 µg/ml was predictive of significantly lower 
disease activity, as measured by CRP. These results were corroborated by Bortlik et al. who found 
that infliximab TC greater than 3 μg/ml at start of maintenance treatment (week 14 or week 22) were 
predictive of sustained remission (median 2-year follow-up) with a positive and negative predictive 
value of, respectively, 85 and 45% in a cohort of 84 CD patients (25). 
Adalimumab Therapeutic Cut-Off 
For adalimumab a similar correlation between the mean trough concentrations and clinical outcome 
was found during the pivotal CLASSIC 1 trial but a recent post hoc analysis of both CLASSIC 1 and 2 
trials was not able to delineate a reliable therapeutic cut-off (26). The authors attributed this to 
overlap in TC between Crohn’s disease patients with and without remission, due to high inter- and 
intra-individual variability. Recently, the exposure-response relationship for adalimumab during the 
induction phase of treatment of UC (ULTRA 2) was investigated (27). From the 258 UC patients 
randomized to receive adalimumab (160/80 mg at weeks 0/2, and 40 mg every other week) the 
relationship between week 8 remission or response and TC was explored. The ranges of adalimumab 
TC quartiles were <5, 5-8.7, 8.7-11.7 and >11.7 µg/ml. Plotting the % of patients in remission per TC 
quartile showed a clear exposure-response relationship at week 8. Higher TC values were associated 
with higher rates of remission. Quartile plots for response showed that the % of patients with week 8 
response was higher for the 2nd and 3rd TC quartiles compared with the 1st quartile. The percentage 
of patients with week 8 response did not increase beyond the 3rd quartile. The authors also 
observed that weight, CRP, albumin, and combination therapy with methotrexate at baseline greatly 
influenced the PK of adalimumab during induction which explained a part of the observed variability 
in drug TC. Regarding maintenance therapy, a prospective cross-sectional study from Velayos F. et al. 
including 54 IBD patients investigated the correlation between adalimumab TC and clinical outcome 
(28). An adalimumab TC <5 µg/ml was found to be correlated with increased levels of CRP. These 
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results were corroborated in a study including 66 IBD patients where elevated CRP levels were best 
predicted by a minimum serum adalimumab cut-off point of 5 µg/ml (29). Similarly, a study including 
40 CD patients treated with maintenance adalimumab revealed that an adalimumab TC cut-off of 5.9 
µg/ml was optimal to maintain negative CRP (≤3 mg/l) (30). Aside from clinical response and 
remission, mucosal healing has emerged as an important therapeutic endpoint in IBD. The 
correlation between adalimumab TC during maintenance therapy and mucosal healing was recently 
investigated in a cohort of 40 IBD patients (31). An adalimumab TC <4.9 µg/ml was found to be 
associated with absence of mucosal healing with a positive predictive value of 88% and negative 
predictive value of 51%. 
TDM at Time of Secondary Loss of Response 
Other than for ‘target concentration adjusted dosing’, TDM can also be used to guide therapy at time 
of loss of response to the biologic. The empiric approach to tackle loss of response by intensifying the 
treatment and, if this fails, switching to another type of TNF inhibitor is frequently suboptimal and 
leads to unnecessary high costs. A therapeutic strategy has several advantages over the empiric 
approach as it 1) avoids dose intensification in those patients who will not benefit from more drug 
(i.e. patients who have become immunized or patients who have a non-TNF driven disease or other 
causes of symptoms) 2) allows targeted dose intensification in those patients who lost response due 
to low concentrations of drug, and 3) directs patients with a non-TNF driven disease more efficiently 
to other therapeutic options. In a simulated model, the testing-based strategy has shown to be more 
cost-efficient compared to the empiric dose-escalation strategy in CD patients losing response to IFX 
(32). Both strategies yielded a similar proportion of patients in response and remission at 52 weeks, 
however this was achieved differently between the two groups.  More patients from the testing 
group needed surgery compared to the empiric group (48 vs. 34% respectively). The main reasons for 
cost savings in the testing group resulted from 1) substantially lower use of high-dose (and high-cost) 
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biological therapy, and 2) greater time spent off biologic medication as compared to the empiric 
group. 
Recently, in Denmark, a first randomized controlled study was performed where individualized 
therapy was compared to standard dose intensification in 69 CD patients with secondary infliximab 
failure (33). Treatment of patients in the active arm was based solely on infliximab drug and ADA 
concentrations. The study revealed that the individualized approach based on drug and ADA 
concentrations was more cost-effective (up to 56% reduction in cost) as compared to routine dose 
escalation, without any apparent effect on clinical efficacy. However, the duration of the study was 
limited to 12 weeks and thus long-term benefits (both pharmacoeconomical and clinical) for this 
approach could not be calculated or predicted. 
A large multi-center, randomized controlled trial is planned in North-America, Canada and Europe 
including 40 investigative sites and 160 IBD patients with secondary loss of response (NCT01960426 
ClinicalTrials.gov). The duration of this study will be 32 weeks and patients will have multiple time 
points at which treatment can be optimized based on drug and ADA concentrations. The study will 
also take into account adalimumab and will give a better representation of the impact of a testing- 
based strategy with respect to the North American healthcare model. 
Recently a study by Paul and co-workers looked at infliximab TC, ADA and endoscopic improvement 
(mucosal healing) after dose escalation in IBD patients suffering secondary loss of response (34). This 
prospective observational study in 52 IBD patients showed that the restoration in infliximab TC after 
dose escalation was correlated with mucosal healing. They found that a cut-off of 0.5 µg/ml was 
associated with mucosal healing (sensitivity 88%, specificity 77%). 
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TDM During Induction and Maintenance Phase 
One could hypothesize that better disease control could be achieved by dose optimizing patients 
based on individual drug TC to intervene before clinical loss of response is diagnosed. Ultimately, this 
might reduce the high rate of loss of response seen during anti-TNF maintenance treatment (35). 
Although there is no incontrovertible proof that adverse events are associated with supratherapeutic 
concentrations of TNF inhibitor, an association between skin lesions, arthralgia and high anti-TNF 
concentrations has been suggested in IBD (36). Therefore, lowering the dose in patients with 
supraoptimal TC could lead to fewer side effects and a lesser cost for the health care payer. A cost-
effectiveness analysis using a patient level Markov model showed important cost savings when a 
personalized treatment based upon drug and ADA concentrations was implemented in a cohort of 
rheumatoid arthritis patients treated with maintenance adalimumab (37). 
Recently, the final results of the randomized controlled TAXIT (trough level adapted infliximab 
treatment; 2011-002061-38 ClinicalTrialsRegister.eu) study have been presented. This study 
investigated whether dosing of infliximab based on TC was superior compared to clinically based 
dosing. The study was comprised of two phases. During the optimization phase, all patients were 
dose-optimized using the TAXIT algorithm to achieve infliximab TC between 3 and 7 µg/ml. This 
revealed that dose escalation in CD patients with suboptimal drug concentrations (<3 µg/ml) leads to 
a better disease control as seen by a significant drop in the Harvey-Bradshaw index and CRP. 
Meantime, dose de-escalation was successful in both CD and UC patients with supra-optimal drug 
concentrations (>7 µg/ml) leading to a lower drug exposure and lower cost (38). During the 
maintenance phase patients were randomized 1:1 to continue drug concentration-based dosing or to 
switch back to clinically-based dosing (52-week follow-up). The primary end point was defined as the 
proportion of patients in clinical and biochemical remission in each group. This second phase of the 
study showed no additional benefit in utilizing an ongoing drug concentration-based dosing strategy 
compared to a clinically-based dosing strategy with infliximab, although the secondary endpoint 
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looking at need for dose optimization clearly showed a benefit for the drug concentration based 
dosing group (39). 
It can be hypothesized that to achieve most out of TDM and ‘target concentration adjusted dosing’, 
one should perform the dose optimization of the drug early on (i.e. during or right after induction) 
(40, 41). A randomized controlled trial (TAILORIX) is under way in Europe, which includes anti-TNF 
naïve CD patients in whom infliximab therapy is initiated (NCT01442025 ClinicalTrials.gov). Dose 
adjustments in the active arm can already be done at week 14 after the start of the treatment based 
on drug concentrations and/or clinical symptoms.  
In the setting of the reintroduction of infliximab therapy after a long drug holiday, adequate drug TC 
and absence of ADA early after restart has been shown to correlate significantly with both short- and 
long-term clinical outcomes (42). 
Monitoring of ADA 
A recent meta-analysis including 1,378 patients with IBD showed that patients who develop 
antibodies to infliximab have a risk ratio of 3.2 (95% confidence interval 2.0–4.9) to lose clinical 
response to the drug as compared to patients who did not develop antibodies. Development of ADA 
also resulted in lower infliximab trough concentration (43). Although the association between ADA 
and hypersensitivity and/or persistent loss of response was already shown a decade ago, quantitative 
correlations between the concentration of ADA and markers of disease activity seem to be limited to 
the presence or absence of ADA. This was recently confirmed in a cross-sectional study including 66 
IBD patients treated with maintenance adalimumab (29). Here, detectable antibodies to adalimumab 
where associated with an adalimumab TC <5 μg/mL [odds ratio (OR) 8.6; 95% CI: 2.3-31.8], 
macroscopic mucosal inflammation [OR 3.8; 95% CI: 1.1-13.2], need for corticosteroids [OR 3.7; 95% 
CI: 1.1-12.9], and previous infliximab use [OR 3.9; 95% CI: 1.0-15.2]. A recent observational 
retrospective study including 90 IBD patients treated with infliximab revealed that, in almost 1/3 of 
IBD patients, antibodies disappeared over time (44). These antibodies were classified as ‘transient’ 
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and led to a discontinuation of the treatment in only 13% of the patients as compared to 68% of the 
patients who developed ‘sustained antibodies’. Interestingly, an infliximab TC <2 µg/ml at week 14 
after start of therapy predicted ADA formation later on. These results have recently been 
corroborated in another prospective observational cohort (45). Dose escalation to overcome low 
level ADA and regain adequate TC has been suggested, but it remains a matter of debate whether 
this is the most cost-effective option. Other options such as adding an immunomodulator (if possible) 
or switching to another anti-TNF have to be considered and prospective studies are warranted (46). 
TDM for Non-Anti-TNF Drugs in IBD 
Therapeutic drug monitoring has also been used in IBD patients treated with azathioprine (AZA) or 6-
mercaptopurine (6-MP) to optimize and to restore clinical response. These drugs are inactive pro-
drugs and are metabolized into the active thioguanine nucleotides (TGN) which can be monitored for 
therapeutic efficacy. A recent study including 189 adult IBD patients showed that the optimization of 
AZA or 6-MP treatment using TGN monitoring resulted in improved clinical outcomes (47). When 
TGN concentrations were taken into account to guide therapy, this resulted in an improved clinical 
effect in 90% of the patients versus only 33% when the treatment decision was not TGN-guided. An 
algorithm to optimize treatment with azathioprine or 6-methotrexate based on TDM has recently 
been suggested elsewhere (48). However, whether or not dose optimization in patients with 
subtherapeutic 6-TGN concentrations results in an increase of 6-TGN concentrations and an 
increased efficacy is still unclear. 
Conclusions and Guidelines 
Based on this literature overview, several guidelines can be formulated on how therapeutic drug 
monitoring could be implemented in clinical practice (Table 1). 
Adequate drug concentrations early after start are associated with better long-term clinical 
outcomes, whereas low or undetectable drug concentrations are associated with loss of response 
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and anti-drug antibody formation. Prospective data are lacking whether dose optimization based on 
early drug concentrations can alter clinical outcomes in the long-term. 
From recent concentration-effect studies in both Crohn’s disease and ulcerative colitis patients, it can 
be suggested that the optimal therapeutic trough concentration during maintenance therapy is 3 
µg/ml for infliximab and 5 µg/ml for adalimumab. For the implementation of therapeutic drug 
monitoring during maintenance therapy, a distinction should be made between 1) responder 
patients where it could help to further optimize dosing of the drug or 2) non-responder patients 
where it could help to guide therapeutic decisions.  
Regarding the first situation, the TAXIT study showed that infliximab dosing based on drug trough 
concentrations results in a more efficient use of drug. However, in patients on longstanding 
biological therapy, it was not necessary to constantly monitor these drug concentrations as clinically-
based dosing proved to be equally effective after the initial drug concentration-based dose 
optimization. 
With regard to the second situation of loss of response during maintenance therapy, drug 
concentration-guided treatment adjustment is likely to be more cost-effective than empiric dose 
escalation at similar clinical outcomes. Given the association between the restoration of infliximab 
and adalimumab trough concentrations and disease response after the intervention measuring drug 
concentrations after dose escalation may still be useful. Therefore in the setting of secondary loss of 
response, consecutive measurements of drug concentrations should be considered. Moreover since 
anti-drug antibodies can be transient, it is useful to measure drug and anti-drug antibodies on 
consecutive time points to confirm this dynamic profile. 
In order to better use therapeutic drug monitoring in routine clinical practice, several hurdles remain 
to be overcome. First, because of a large inter-individual variability in drug trough concentration, it is 
difficult to define a trough concentration window which is optimal for each patient. Factors 
influencing infliximab and adalimumab PK have been described (e.g., body weight, serum albumin 
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concentration, and presence of ADA) but do not account for all the variability (27, 49). Therefore, 
intensive PK sampling in large patient cohorts would seem necessary to define important 
determinants of PK. Second, it is crucial that accurate and accessible techniques can be used to 
measure drug and ADA concentrations. Correlations between established assays are lacking and 
standardization is necessary to reduce assay-related variability. The cost of these measurements is 
also an important factor, as this will influence the cost-effectiveness of therapeutic drug monitoring 
(although the cost of biologic medications is so great that even relatively expensive assays are still 
cost effective compared to empiric dose escalation). Third, prospective data of the implementation 
of a TDM approach in routine clinical practice remain scarce, but trials are under way. These results 
will further answer the question of whether or not therapeutic drug monitoring is superior to the 
empiric dose adjustment approach and which strategy is more cost-effective. 
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Tables 
Table 1 Implementation of a therapeutic drug monitoring approach of anti-TNF drugs in the treatment of inflammatory bowel disease 
patients. 
 
  Serum Drug Concentration 
  
High Optimal range Low 
  
Response to 
treatment 
Maintained 
remission 
Dose reduction 
Dosing scheme 
unchanged 
Measure ADA: 
 
Sustained ADA 
Stop and consider switch out of class 
Transient or Undetectable ADA 
Dose optimize/switch in class  
Or 
Consider to stop and switch out of class when 
mucosal healing is confirmed by endoscopy 
Partial or loss 
of response 
aSwitch out of class aSwitch out of class 
Measure ADA: 
 
Sustained ADA 
Stop and switch in class 
Transient ADA 
Dose optimize/switch in class 
ADA undetectable 
Dose optimize and determine cause of accelerated 
drug clearance 
(e.g., consider endoscopya) 
ADA anti-drug antibody 
aRule out non-IBD causes of symptoms 
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Legend to figures 
Figure 1 Post hoc analysis of data from ACT 1 and ACT 2 trials representing the proportion of patients 
achieving clinical remission by serum infliximab concentration. Clinical remission was defined as 
Mayo Score ≤2 points, with no individual subscore >1. X-axis represents quartiles (Q) of infliximab 
trough concentration in µg/ml and were for week 8: Q1 <21.3; Q2 ≥21.3-<33.0; Q3 ≥33.0-<47.9 and 
Q4 >47.9; for week 30: Q1 <0.11; Q2≥0.11-<2.4; Q3 ≥2.4-<6.8 and Q4 >6.8; for week 54: Q1 <1.4; Q2 
≥1.4-<3.6; Q3 ≥3.6-<8.1 and Q4 >8.1. Adapted from Reinisch W. et al., Infliximab Concentration and 
Clinical Outcome in Patients With Ulcerative Colitis. Presented at Digestive Disease Week; May 19-22, 
2013; San Diego, California. Abstract 566 
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